Heritage.ai Spółka z Ograniczoną Odpowiedzialnością (KRS 0001034190, NIP 5252955132) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. HERITAGE.AI operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since May 8, 2023. HERITAGE.AI's most recently reported net revenue was 0 PLN for 2024.
Negative equity
Negative equity in 2 of 2 available reporting years.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Heritage.ai
Identity
- Name
- Heritage.ai Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- May 8, 2023
- Registry status as of
- May 4, 2026
- Latest entry
- May 4, 2026
- Founding act
- 27.04.2023 R.
Articles of association history (2)
- April 27, 2023: 27.04.2023 R.
- March 13, 2026: 13.03.2026 R., REP. A NR 3170/2026, NOTARIUSZ SŁAWOMIR WIŚNIEWSKI, KANCELARIA NOTARIALNA W WARSZAWIE PRZY UL. GAŁCZYŃSKIEGO 4, ZMIANA § 5 UMOWY SPÓŁKI, DODANIE W § 6 PO PKT 1 PKT 2 UMOWY SPÓŁKI.
Activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. KRAKOWSKIE PRZEDMIEŚCIE, 13, 00-071, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-78969-37978-TSSBA-25
Risk and payment profile - Heritage.ai
Credibility rating
1.7 / 100
Very poor credibility
Insolvency risk
Very high
Significant formal threat
Closure risk
57
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/3 yrs
Board changes
1
1/3 yrs
PKD changes
0
0/3 yrs
Name changes
0
0/3 yrs
Data from 3 years of registry activity.
Credibility history
Payment reliability score from 2023–2024
Current: E (2/100)
Trend: deteriorating (-5.2 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2023–2024
Current: 0 PLN
Safe: 0 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Heritage.ai
Founded
May 8, 2023
3 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
1.0 M PLN
10,050 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
2 years
2023–2024 · profitable: 0/2
Registry entries
12
latest: May 4, 2026
Risk signals
Revenue
0 PLN
2024
Net profit
-116.9 K PLN
2024
Assets
133.3 K PLN
2024
Equity
-144.6 K PLN
2024
EBITDA
-36.9 K PLN
2024
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Heritage.ai.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
